MONTREAL, March 06, 2018 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX:TH) and its partner TaiMed Biologics, Inc. (TaiMed) today announced that the U.S. Food and Drug Administration (FDA) has granted approval of TrogarzoTM (ibalizumab-uiyk).
A conference call will be held today at 4:30 p.m. (ET) to discuss this announcement. The call will be hosted by Luc Tanguay, President and Chief Executive Officer. The conference call will be open to questions from financial analysts. Media and other interested individuals are invited to participate in the call on a “listen-only” basis.
The conference call can be accessed by dialing 1-877-223-4471 (North America) or 1-647-788-4922 (International). The conference call will also be accessible via webcast at http://www.gowebcasting.com/9197. Audio replay of the conference call will be available two hours after the completion of the call and until March 20, 2018, by dialing 1-800-585-8367 (North America) or 1-416-621-4642 (International) and by entering the playback code 9059158.
About Theratechnologies
Theratechnologies (TSX:TH) is a specialty pharmaceutical company addressing unmet medical needs to promote healthy living and an improved quality of life among HIV patients. Further information about Theratechnologies is available on the Company's website at www.theratech.com and on SEDAR at www.sedar.com.
INFORMATION:
Contact: Chantal Plaçais
Phone: 514.336.7800 ext. 233